Latest Strategy News

Global X Management (AUS) Limited has announced estimated distributions for three ETFs listed on the ASX AQUA Market for the period ending 31 July 2025, including details on distribution amounts and key dates.

Patrys Limited has launched a fully underwritten entitlement offer to raise approximately $1.77 million, aiming to accelerate development and commercial activities around its deoxymabs program.

Hillgrove Resources outlined its operational progress and growth strategy at the Noosa Mining Investor Conference, highlighting strong cash flow and resource expansion at its Kanmantoo Copper Gold Mine.

The Supreme Court of New South Wales has approved the acquisition scheme for AVJennings Limited, paving the way for a significant ownership change and imminent suspension of its shares on major exchanges.

Rimfire Pacific Mining Limited has had its trading suspension lifted immediately following the release of its capital raising results, signaling renewed market activity.

Rimfire Pacific Mining has secured $3.5 million through a discounted share placement to accelerate scandium resource development across its NSW projects, signaling renewed momentum after arbitration setbacks.

Fat Prophets Global Contrarian Fund Ltd announces a special fully franked dividend of AUD 0.05 per share, coupled with a dividend reinvestment plan offering a 2.5% discount. Key dates for investors are set for late August and September 2025.

Karoon Energy announces CEO Dr Julian Fowles will depart by mid-2026 as the company relocates key corporate roles to Brazil and the USA, initiating a global search for a Houston-based successor.

Astute Metals NL sharpens its focus on Nevada’s rich mineral landscape, unveiling fresh high-grade gold targets at Needles and reaffirming lithium potential at Red Mountain amid leadership changes.

Santana Minerals reports compelling new assay results extending the high-grade gold domain at its Rise and Shine deposit, reinforcing prospects for resource upgrades and future reserve growth.

Pengana International Equities Limited has announced a fully franked ordinary dividend of AUD 0.0135 per share for the quarter ending June 2025, with a Dividend Reinvestment Plan available to shareholders.

Amplia Therapeutics has launched a $27.5 million capital raising to advance its lead drug Narmafotinib, a promising FAK inhibitor showing superior efficacy in pancreatic cancer trials. The funds will support ongoing and new clinical studies, positioning the company for pivotal regulatory milestones.